Financial Health Assessment: FUTURE PRODUCTS LIMITED

1. Financial Health Score: C+

Explanation: The patient is fundamentally alive and showing signs of revenue growth, but is exhibiting worrying symptoms of cash depletion that require urgent attention. While the underlying business generates turnover of nearly £20 million and maintains profitability, the dramatic deterioration in liquid reserves suggests the company is stretching its financial arteries dangerously thin to fuel growth and reward shareholders.

2. Key Vital Signs

Revenue (Turnover)

Diagnosis: Revenue has recovered well from the 2024 dip, returning to near-2022 levels. The 14.8% growth is a healthy pulse rate, though the business experienced a two-year contraction before this recovery. This pattern suggests cyclical sensitivity rather than consistent growth.

Profitability

• Pre-tax profit (2025): £289,661
• Pre-tax profit (2024): £74,243 (impacted by £404,391 exceptional stock impairment)
• Gross margin: Stable at 24.6%
• Net profit margin (2025): Approximately 1.5%

Diagnosis: The gross margin of 24.6% is reasonable for manufacturing, but the net profit margin is anaemic at just 1.5% of turnover. For a business turning over nearly £20 million, pre-tax profits of under £300K represent extremely thin gruel. The 2024 figure was artificially depressed by an exceptional item, but even the "clean" 2025 figure demonstrates limited bottom-line efficiency.

Cash Position – CRITICAL ALERT

Diagnosis: This is the most alarming vital sign. Cash has plummeted by 85% in a single year and has fallen by 92.5% from the 2022 peak. At just 0.8% of turnover, the company has less than three days' worth of revenue in liquid reserves. For a manufacturer with significant working capital needs, this is a dangerously low immune response – the financial equivalent of a patient with critically low blood pressure.

Net Assets & Shareholders' Funds

Diagnosis: Net assets have stabilised around the £2.4-2.5 million mark over recent years, representing a remarkable recovery from the 2019 low of £566K. However, the stability is somewhat illusory – while the balance sheet appears steady, the composition has shifted dramatically from liquid to illiquid assets.

Leverage (Liabilities to Assets)

Diagnosis: Leverage has increased significantly from 56% in 2023 to 63% in 2025, with liabilities growing by over £1 million in two years. The company is financing asset growth through debt rather than retained earnings, increasing its financial vulnerability.

Dividend Policy

• 2025: £201,032
• 2024: £109,990

Diagnosis: Dividends have nearly doubled despite the cash crisis. This represents a significant outflow at a time when the business should arguably be conserving resources. Paying out 69% of pre-tax profits as dividends while cash reserves collapse is the financial equivalent of continuing heavy exercise despite cardiac distress.

3. Diagnosis

Overall Condition: Stable but Strained

Future Products Limited presents a paradoxical financial picture – a business that appears fundamentally healthy on the surface but is experiencing significant internal stress.

The Core Problem: The company is suffering from what I would term "asset-rich, cash-poor syndrome". Total assets have grown impressively from £2.3 million in 2018 to £5.9 million in 2025 – a 157% increase. However, this growth has been achieved by: - Taking on significantly more debt (liabilities up from £1.85 million to £3.72 million) - Depleting cash reserves (down from £332K in 2018 to £152K in 2025, with a peak of £2 million in 2022) - Paying out increasing dividends rather than retaining profits

Symptoms of Concern:

1. Cash Haemorrhage: The £867K decline in cash during 2025 (from £1.02 million to £152K) cannot be fully explained by dividends alone (£201K). This suggests significant capital expenditure or working capital absorption. The accounts reference hire purchase contracts and leased assets, indicating the company is financing fixed asset purchases through debt rather than cash.

2. Working Capital Pressure: With turnover growing by £2.55 million but cash declining by £867K, the business is likely experiencing increased debtor days and/or stock holding. The 2024 exceptional impairment of old stock (£404K) suggests inventory management has been a historical issue.

3. Low Profit Conversion: Despite £19.8 million turnover, only £289K reaches pre-tax profit – a 1.5% net margin. This suggests either significant cost pressures or that the business model requires substantial overhead to generate revenue.

4. Debt-Financed Growth: The increase in total liabilities from £2.6 million (2023) to £3.7 million (2025) – a £1.1 million increase – alongside the asset growth, indicates the business is leveraging up to fund expansion.

Positive Indicators:

1. Revenue Recovery: The 14.8% revenue growth shows market demand remains strong
2. Gross Margin Stability: 24.6% gross margin is maintained, suggesting pricing power and cost control at the production level
3. Long Track Record: Operating since 1993, the business has survived multiple economic cycles
4. Net Asset Recovery: From near-insolvency in 2019 (£566K net assets), the balance sheet has been substantially rebuilt
5. Reduced Competition: The strategic report notes reduced competition in their sector, creating opportunities

4. Prognosis

Short-term (6-12 months): CAUTIOUS

The immediate risk is a liquidity crisis. With only £152K in cash against £19.8 million turnover and £3.7 million in liabilities, any disruption to cash collection, unexpected costs, or further capital requirements could create serious difficulties. The company's reliance on invoice financing provides some buffer, but this is debt that must be serviced.

Medium-term (1-3 years): GUARDED BUT IMPROVING

If the company can stabilise its cash position and convert its asset investments into profitable returns, the prognosis improves. The revenue growth and market position provide a solid foundation. However, the thin profit margins mean there is little room for error.

Key Risk Scenarios:

1. Customer payment delays could quickly cascade into a cash crisis
2. Interest rate increases on the £3.7 million debt pile would further compress margins
3. Economic downturn reducing construction activity (their market) would hit both revenue and debtor collection
4. Further dividend payments at current levels would continue to weaken the balance sheet

5. Recommendations

Immediate Actions (Urgent)

1. Cash Stabilisation Protocol: Implement an immediate cash conservation programme. Target a minimum cash reserve of 5% of turnover (approximately £1 million) as an emergency fund. This may require: - Negotiating extended payment terms with suppliers - Accelerating debtor collection through proactive credit management - Considering whether current capital expenditure plans can be phased

2. Dividend Restraint: Suspend or significantly reduce dividend payments until cash reserves reach a healthy threshold. Paying £201K in dividends while cash drops by £867K is financially irresponsible and risks the long-term health of the business.

3. Working Capital Audit: Conduct an immediate review of: - Debtor days and collection performance - Stock levels and turnover rates - Creditor payment terms - Invoice financing costs and terms

Medium-term Improvements

4. Profit Margin Enhancement: With a 24.6% gross margin converting to only 1.5% net margin, there is a 23.1% cost gap between gross and net profit. Review overhead structure, operational efficiency, and pricing strategy to improve bottom-line performance. Target a minimum 3-4% net margin.

5. Debt Structure Review: With £3.7 million in liabilities, review the cost and terms of all financing arrangements. Consider whether the current mix of invoice financing, hire purchase, and other debt is optimal, or whether refinancing could reduce costs and improve cash flow.

6. Capital Expenditure Planning: The apparent investment in fixed assets should be part of a clear strategic plan with defined return expectations. Ensure all capital investments have robust business cases with payback periods that align with the financing terms.

7. Cash Flow Forecasting: Implement rolling 13-week cash flow forecasting to provide early warning of potential liquidity shortfalls. This should be a board-level report reviewed weekly.

Strategic Considerations

8. Market Position Leverage: The strategic report notes reduced competition in the sector. Explore whether this creates opportunities for pricing improvements or market share gains that could enhance profitability.

9. Succession Planning: With key PSCs including Dennis Harold Thorpe (likely connected to the director of the same name), ensure robust succession and management continuity plans are in place.

10. Financial Reporting Enhancement: Consider voluntary disclosure of cash flow statements and more detailed breakdowns of current assets to provide stakeholders with better visibility of the company's liquidity position.

Summary Dashboard